Mode
Text Size
Log in / Sign up
Phase 3 Completed N=47 Randomized Treatment

Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure

Source: ClinicalTrials.gov NCT05093621 ↗
Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcomePrimary: Number of Participants All-cause Mortality, Measured at 1 Year. — 0; 0; 0; 1 Participants — p=1.000
◆ Published Evidence
Emerging
18citations · ~18 / year
Mechanistic Differences between Torsemide and Furosemide.
Journal of the American Society of Nephrology : JASN · 2025 · Open access · Likely link

Summary

The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of loop diuretics.

Linked Publications

  • Mechanistic Differences between Torsemide and Furosemide.
    Journal of the American Society of Nephrology : JASN · 2025 · 18 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants All-cause Mortality, Measured at 1 Year.
0; 0; 0; 1 1.000
SECONDARY
All-cause Hospitalization
6; 7 0.729
SECONDARY
Total Hospitalizations
0; 0 0.650
SECONDARY
Change in Weight
-1.84; -3.04 0.873

Eligibility Criteria

Inclusion Criteria

  • Patients with a diagnosis of heart failure and who have been on a stable dose of a diuretic for at least 30 days.
  • Plan for a daily outpatient oral loop diuretic regimen with anticipated need for long term loop diuretic use
  • ≥ 18 years of age
  • Signed informed consent

Exclusion Criteria

  • End-stage renal disease requiring dialysis therapy
  • Inability or unwillingness to comply with the study requirements
  • History of heart transplant or actively listed for heart transplant
  • Implanted left ventricular assist device or implant anticipated <3 months
  • Pregnant or nursing women or women who are trying to conceive
  • Malignancy or other non-cardiac condition limiting life expectancy to <12 months
  • Known hypersensitivity to furosemide, torsemide, or related agents
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05093621) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search